Fosfomycin: Difference between revisions
From IDWiki
No edit summary |
(→: renal dosing) |
||
| Line 36: | Line 36: | ||
=== Renal Dosing === |
=== Renal Dosing === |
||
* |
* Oral: no dosage adjustment necessary for oral, though elimination may be prolonged |
||
* Intravenous |
|||
* CrCl 40 to 80 mL/min: normal dose |
|||
** CrCl >=130 mL/min: maximum indicated dose for indication (up to 24 g/day in 3 to 4 divided doses) |
|||
| ⚫ | |||
* CrCl |
** CrCl 40-129 mL/min: normal dose, in 2 to 4 divided doses |
||
* CrCl |
** CrCl 30-39: 70-80% of normal daily dose, in 2 to 3 divided doses |
||
* CrCl |
** CrCl 20-29: 50-70% of normal daily dose, in 2 to 3 divided doses |
||
** CrCl 10-19: 30-50% of normal daily dose, in 2 to 3 divided doses |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
==Safety== |
==Safety== |
||
Revision as of 14:40, 15 October 2022
Background
Mechanism of Action
- Inhibits an enzyme-catalyzed reaction in cell wall synthesis
- Bacteridical
Spectrum of Activity
- Active against many Gram-positive bacteria, including MSSA, MRSA, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and VRE
- Active against many Gram-negative bacteria, including regular Enterobacterales, CRE, and ESBL
- Unclear if effective against Pseudomonas
- Limited activity against gut anaerobes, but does cover Peptostreptococcus
- Intrinsic resistance in Acinetobacter, Stenotrophomonas maltophilia, Burkholderia cepacia, some coagulase-negative staphylococci (Staphylococcus capitis and Staphylococcus saprophyticus), Morganella morganii, and Mycobacterium tuberculosis
PK/PD
- Efficacy predicted by time above MIC
- Oral bioavailability 34 to 58%; higher if taken on an empty stomach
- Elimination half-life of 5.7 hours, 93 to 99% excreted unchanged in the urine
Breakpoints
- Determined by agar (not broth) dilution
- Enterobacterales: susceptible if MIC ≤32, resistance if MIC >32
- Pseudomonas aeruginosa: no MIC breakpoints; ECV is 128 mg/L
- Acinetobacter: no MIC breakpoints or ECV
Dosing
- Uncomplicated UTI: fosfomycin 3 g PO once
- Complicated UTI: fosfomycin 3 g PO q72h for 2 to 3 doses
- Intravenous: fosfomycin disodium 8 g IV q12h
- CNS or other severe infection: fosfomycin disodium 8 to 12 g IV q12h
Renal Dosing
- Oral: no dosage adjustment necessary for oral, though elimination may be prolonged
- Intravenous
- CrCl >=130 mL/min: maximum indicated dose for indication (up to 24 g/day in 3 to 4 divided doses)
- CrCl 40-129 mL/min: normal dose, in 2 to 4 divided doses
- CrCl 30-39: 70-80% of normal daily dose, in 2 to 3 divided doses
- CrCl 20-29: 50-70% of normal daily dose, in 2 to 3 divided doses
- CrCl 10-19: 30-50% of normal daily dose, in 2 to 3 divided doses
- CrCl <10: 20% of normal daily dose, in 1 to 2 divided doses
- Intermittent hemodialysis: 2 g after each session (up to 4 g for severe or less susceptible infections)
Safety
Monitoring
- Hypokalemia, high sodium content, dose-limiting nausea, vomiting, and diarrhea
Pregnancy
- Safe in pregnancy
References
- ^ Roberta Maria Antonello, Stefano Di Bella, Alberto Enrico Maraolo, Roberto Luzzati. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies. European Journal of Clinical Microbiology & Infectious Diseases. 2021;40(6):1117-1126. doi:10.1007/s10096-021-04181-x.
